StockNews.com Initiates Coverage on Neptune Wellness Solutions (NASDAQ:NEPT)

StockNews.com began coverage on shares of Neptune Wellness Solutions (NASDAQ:NEPTGet Rating) (TSE:NTB) in a research report issued on Friday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Zacks Investment Research lowered Neptune Wellness Solutions from a “buy” rating to a “hold” rating in a research note on Wednesday, April 13th.

NASDAQ:NEPT opened at $0.14 on Friday. The stock has a 50-day simple moving average of $0.22 and a two-hundred day simple moving average of $0.35. Neptune Wellness Solutions has a 52-week low of $0.13 and a 52-week high of $1.49. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.07 and a current ratio of 1.75. The firm has a market capitalization of $27.22 million, a PE ratio of -0.25 and a beta of 2.07.

Neptune Wellness Solutions (NASDAQ:NEPTGet Rating) (TSE:NTB) last released its quarterly earnings data on Thursday, February 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The business had revenue of $14.63 million during the quarter, compared to the consensus estimate of $13.64 million. Neptune Wellness Solutions had a negative return on equity of 73.19% and a negative net margin of 207.14%. Equities analysts forecast that Neptune Wellness Solutions will post -0.32 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of NEPT. Goldman Sachs Group Inc. lifted its position in shares of Neptune Wellness Solutions by 2,047.4% in the third quarter. Goldman Sachs Group Inc. now owns 3,005,884 shares of the biotechnology company’s stock worth $1,817,000 after buying an additional 2,865,906 shares in the last quarter. Penserra Capital Management LLC raised its position in Neptune Wellness Solutions by 53.2% during the third quarter. Penserra Capital Management LLC now owns 2,403,104 shares of the biotechnology company’s stock valued at $1,452,000 after purchasing an additional 834,504 shares during the period. Renaissance Technologies LLC purchased a new stake in Neptune Wellness Solutions during the fourth quarter valued at approximately $184,000. Morgan Stanley raised its position in Neptune Wellness Solutions by 256.1% during the third quarter. Morgan Stanley now owns 503,122 shares of the biotechnology company’s stock valued at $304,000 after purchasing an additional 361,853 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Neptune Wellness Solutions during the fourth quarter valued at approximately $64,000. Institutional investors own 8.89% of the company’s stock.

About Neptune Wellness Solutions (Get Rating)

Neptune Wellness Solutions Inc, a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils.

Featured Stories

Receive News & Ratings for Neptune Wellness Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neptune Wellness Solutions and related companies with MarketBeat.com's FREE daily email newsletter.